Dexrazoxane prevents vascular toxicity in doxorubicin-treated mice

Dexrazoxane prevents vascular toxicity in doxorubicin-treated mice

Abstract Background Doxorubicin (DOX) is used for breast cancer and lymphoma, but can cause cardiotoxicity, arterial stiffness, and endothelial dysfunction. We recently reported SERPINA3N as biomarker of cardiovascular toxicity in patients and mice. Dexrazoxane (DEXRA) is an FDA-approved drug that p...

Full description

Bibliographic Details
Main Authors: Dustin N. Krüger, Matthias Bosman, Emeline M. Van Craenenbroeck, Guido R. Y. De Meyer, Constantijn Franssen, Pieter-Jan Guns
Format: Article
Language:English
Published: BMC 2024-10-01
Series:Cardio-Oncology
Subjects:
Doxorubicin
Dexrazoxane
Vascular toxicity
Endothelial cell dysfunction
SERPINA3
Online Access:https://doi.org/10.1186/s40959-024-00270-w

Internet

https://doi.org/10.1186/s40959-024-00270-w

Similar Items